Ra Capital Management Q2 2026 Portfolio Update: Strategic Shifts in Healthcare Focus

As of June 30, 2026, Ra Capital Management has maintained its significant concentration in the Healthcare sector for their portfolio.

The investor's holdings include several notable companies within this space. Among the top weighted positions are Rhythm Pharmaceuticals (RYTM), Vaxcyte (PCVX), Tyra Biosciences (TYRA), and Edgewise Therapeutics (EWTX). These established stakes show no change in share count during this quarter.

However, Ra Capital Management has also made observable changes to its portfolio structure. The most significant activity involves new positions or substantial increases in existing ones:

• ABIVAX SA-ADR (ABVX) was added to the portfolio.
• Aura Biosciences, Solid Biopharma, and Nuvelos Pharmaceuticals saw their share counts increase significantly during this period.
• The investor notably rebuilt positions in several companies: Sana Biotechnology (SANA), Editas Medicine (EDIT), Altimmune (ALT), and Prelude Therapeutics (PRLD).
• Additionally, Ra Capital Management increased its stake in Aclaris Therapeutics (ACRS) by nearly 87%.

This quarter also saw the investor exit or reduce positions in certain Healthcare companies:

• Q32 Bio (QTTB) was added, but its significance is limited by a small portfolio allocation.
• The investor sold shares in Nuvaant Inc-A (NUVL), reducing their stake there by nearly half (-50.81%).
• Werewolf Therapeutics experienced a significant reduction, with Ra Capital Management cutting their position by over 64%.
• The investor also reduced shares in Edgewise Therapeutics (EWTX) by nearly 20%, and completely divested from Disc Medicine (IRON).

These changes reflect a dynamic investment strategy focused on the Healthcare sector, particularly within biotechnology. The portfolio now includes Ra Capital Management LP's stake in companies like Aclaris Therapeutics (ACRS), Sana Biotechnology (SANA), and INTELLIA Therapeutics (NTLA).